KW-8232 free base is an anti-osteoporotic agent that reduces the biosynthesis of prostaglandin E2 (PGE2); it potently increases femoral bone mineral density (BMD) in immobilized legs of rats, ameliorates immobilization-induced abnormal bone turnover, decreases urinary calcium excretion (at 30 mg/kg), and significantly reduces urinary pyridinoline and deoxypyridinoline excretion—markers of bone resorption—in neurectomized rats; its inhibition of bone loss is attributed to reduced prostaglandin (PG)-stimulated bone resorption via regulation of PGE2 production.